(firstQuint)Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer.

 This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757 administered as a short term intravenous (IV) infusion in subjects with small cell lung cancer.

 AMG 757 is a Half Life Extended (HLE) Bispecific T cell engager (BiTE(R)) targeting delta-like protein 3 (DLL3).

 Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer@highlight

A study to assess the safety, tolerability, and pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer